Openbookopenbook
Equity
InMed Pharmaceuticals Inc(INM)
USD --+0.00%
Reward52Moderate
Risk45Moderate
📊75%Data
Thin -170% profit margin · Revenue down 26% YoY
INM
+0.0 · +0.00%
USD · NASDAQ
InMed Pharmaceuticals Inc | Healthcare
Profitless Growth
Market Cap:2.60M
ℹ️
Reward Rating
52
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
45
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on INM to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $20.00.

What is InMed Pharmaceuticals Inc?

, a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States.

INM · Verdict

Moderate reward · moderate risk

INM stands out on volatility and balance sheet, but watch the profitability signal.

Based on 88% data coverage

INM · Verdict

What’s working & what to watch

Strengths 4

  • Volatility80/100

    Top decile vs peers

  • Balance sheet76/100

    Current ratio 6.99

  • Growth68/100

    Rev +65.5% CAGR · earnings -24.0%

  • Valuation67/100

    Above average

Watchouts 2

  • Profitability9/100

    -165% net margin · -97% ROE

  • Cash flow20/100

    -157% free-cash-flow margin

Model-based scoring. For information only — not financial advice.

What is InMed Pharmaceuticals Inc?

, a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.60M.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (52)

The scoring profile indicates limited reward potential at this time, with growth and valuation offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap2.60M
P/E RatioN/A
Dividend YieldN/A
52 Week High5.5
52 Week Low0.8496
Last AnnualJune
IPO Date11/12/2020
IncorporatedUSA
Shares Outstanding3M
No. of Employees13
IndustryDrug Manufacturers - Specialty & Generic
ExchangeNASDAQ
Beta0.395
CurrencyUSD
Websitewww.inmedpharma.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.